Term
|
Definition
Use: HSV, VSV, EBV
MOA: G analog, activated by vTK, +PO4 -> inh. DNA pol. Acyclic nucleotide analog.
Adverse: Well tolerated. Nephrotoxic. Avoid nephrotoxic drugs (zidovudine)
Pharm: Oral, IV, topical. (+)CSF 50% [serum]. |
|
|
Term
|
Definition
Use: CMV
MOA: G analog, activated by vTK, +PO4 -> inh. DNA pol. Acyclic nucleotide analog.
Adverse: More tox than Acyclovir. Nephro, hemo. Potential carcinogen
Pharm: Intravitreal, IV, oral (low F, 6-9%) |
|
|
Term
|
Definition
Use: CMV retinitis alt. to ganciclovir
MOA: Non Nucleoside vDNApol inh. PPi analog
Adverse: Nephro, hypoC++ -> CNS effects. Avoid nephrotoxic drugs, pentamidine
Pharm: IV, renal excretion |
|
|
Term
|
Definition
Use: CMV retinitis alt. to ganciclovir
MOA: Non Nucleoside vDNApol inh. PPi analog
Adverse: Nephro, hypoC++ -> CNS effects. Avoid nephrotoxic drugs, pentamidine
Pharm: IV, renal excretion |
|
|
Term
|
Definition
Use: Flu A prophylaxis and tx
MOA: block uncoating M2 proton channel (mutation resistance)
Adverse: CNS- ataxia, insomnia, confusion, seizures. Interact w antihistamines, antiACh, EtOH
Pharm: oral, nasal and lung secretions
Bonus: Tx parkinson's tremor ++DA++ |
|
|
Term
|
Definition
Use: Flu A&B
MOA: Block vNA -> no sialic acid cleavage
Adverse: Mild GI. *behavior problems* Zanamivir- bronchospasm
Pharm: rapid absorption, renal excretion |
|
|
Term
|
Definition
Use: RNA/DNA viruses. Chronic HepC +interferon. RSV in children.
MOA: ?? G analog inh. IMPDH. Dec viral mRNA capping
Adverse: Hemolytic anemia. Teratogen-6 mo washout.
Pharm: oral. +CSF. ++RBC |
|
|
Term
|
Definition
Use: HIV combo therapy
MOA: NRTI
Adverse: Granulocytopenia, anemia, Lactic acidosis. headache, seizure, myalgia. Resistance fast. MANY Interactions: ASA, Acetominophen, EtOH, Abx, Fluoroquinolones, probenecid, ribavirin
Pharm: Oral, IV. +CSF |
|
|
Term
|
Definition
Use: HIV HAART
MOA: Non-competitive NNRTI
Adverse: ^^protease inh metabolism. Rash, GI. Rapid mutation.
Pharm: Oral. Hepatic met. |
|
|
Term
|
Definition
Use: HIV HAART
MOA: Protease inhibitor. Protease cleaves Gag Pol into p17, p24, p2, p7, p1, p6, protease, RT, INT
Adverse: CYP3A4 competition. N/V/D. Buffalo hump, hyperlycemia, Kidney stones |
|
|
Term
|
Definition
Use: HIV HAART
MOA: Protease inhibitor. Protease cleaves Gag Pol into p17, p24, p2, p7, p1, p6, protease, RT, INT
Adverse: CYP3A4 competition. N/V/D. Buffalo hump, hyperlycemia, Kidney stones |
|
|
Term
| HAART components, advantages, disadvantages |
|
Definition
>3 drug classes per regimen- NRTI, NNRTI, PI
(+) Drops viral RNA #, CD4 rises, opportunistic infection decreases
(-) tricky interactions, non compliance, resistance, no cure |
|
|
